NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$176.49 -0.62 (-0.35 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$177.11
Today's Range$174.88 - $177.59
52-Week Range$128.58 - $184.00
Volume294,879 shs
Average Volume500,164 shs
Market Capitalization$10.61 billion
P/E Ratio18.46
Dividend YieldN/A
Beta0.96
Jazz Pharmaceuticals logoJazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone353-1634-7800

Debt

Debt-to-Equity Ratio0.55
Current Ratio3.00
Quick Ratio2.88

Price-To-Earnings

Trailing P/E Ratio18.46
Forward P/E Ratio15.18
P/E Growth0.96

Sales & Book Value

Annual Sales$1.62 billion
Price / Sales6.57
Cash Flow$13.0540 per share
Price / Cash13.52
Book Value$45.26 per share
Price / Book3.90

Profitability

EPS (Most Recent Fiscal Year)$9.56
Net Income$487.84 million
Net Margins26.51%
Return on Equity23.78%
Return on Assets11.97%

Miscellaneous

Employees1,210
Outstanding Shares60,290,000
Market Cap$10,613.48

Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported $2.98 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.78 by $0.20. The specialty pharmaceutical company earned $444.61 million during the quarter, compared to the consensus estimate of $435.69 million. Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. The business's quarterly revenue was up 18.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.31 earnings per share. View Jazz Pharmaceuticals' Earnings History.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Jazz Pharmaceuticals.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $12.75-13.25 for the period, compared to the Thomson Reuters consensus estimate of $13.00. The company issued revenue guidance of $1.88-1.93 billion, compared to the consensus revenue estimate of $1.89 billion.

What price target have analysts set for JAZZ?

22 brokerages have issued 1 year price objectives for Jazz Pharmaceuticals' stock. Their forecasts range from $150.00 to $219.00. On average, they anticipate Jazz Pharmaceuticals' share price to reach $185.3810 in the next twelve months. This suggests a possible upside of 5.0% from the stock's current price. View Analyst Ratings for Jazz Pharmaceuticals.

What is the consensus analysts' recommendation for Jazz Pharmaceuticals?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 4 hold ratings and 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Jazz Pharmaceuticals stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "After lower-than-expected sales in 2017, Jazz’ sleep disorder drug, Xyrem witnessed improved volume trends in Q1. Management seems confident that Xyrem will continue to generate volume growth in 2018 and beyond. Jazz’s lead pipeline candidate JZP-110 complements its existing sleep disorder portfolio. Meanwhile, its newest drug Vyxeos is enjoying improving demand trends. Jazz is also actively evaluating business development deals to enhance its product line and pipeline. Shares of the company have outperformed the industry so far this year.  However, Jazz has been facing supply constraints for leukemia drug, Erwinaze, due to constrained manufacturing capacity. These supply challenges are expected to continue in 2018. Estimate movement has been mixed ahead of the company’s Q2 earnings release. Jazz has a mixed record of earnings surprises in recent quarters." (7/16/2018)
  • 2. Mizuho analysts commented, "We reiterate our Neutral rating and $150 PT post-1Q:18 beat & improved guidance. We think investors may now be concerned about deal risk in the name." (5/9/2018)
  • 3. Cantor Fitzgerald analysts commented, "JAZZ’s purchase of PRV makes strategic sense to us. This morning, the acquisition of a Priority Review Voucher (PRV) by JAZZ was disclosed. The company is paying $110 million in cash for a PRV owned by Spark Therapeutics (ONCE, Overweight rated covered by Elemer Piros). Particularly when applied to a speed-to-market situation, we believe the PRV could be useful for JAZZ." (4/30/2018)

Who are some of Jazz Pharmaceuticals' key competitors?

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the folowing people:
  • Mr. Bruce C. Cozadd, Co-Founder, Exec. Chairman & CEO (Age 54)
  • Mr. Matthew P. Young, Exec. VP & CFO (Age 49)
  • Ms. Suzanne Sawochka Hooper, Exec. VP & Gen. Counsel (Age 52)
  • Mr. Daniel N. Swisher Jr., Pres & COO (Age 55)
  • Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 55)

Has Jazz Pharmaceuticals been receiving favorable news coverage?

Media stories about JAZZ stock have been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jazz Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also gave news coverage about the specialty pharmaceutical company an impact score of 47.08 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.07%), Hardman Johnston Global Advisors LLC (0.06%), Gateway Investment Advisers LLC (0.05%), Private Capital Advisors Inc. (0.04%), Essex Investment Management Co. LLC (0.03%) and Xact Kapitalforvaltning AB (0.03%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.

Which major investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Hardman Johnston Global Advisors LLC and RDL Financial Inc.. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals.

Which major investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was purchased by a variety of institutional investors in the last quarter, including Private Capital Advisors Inc., Essex Investment Management Co. LLC, Amalgamated Bank, State of Alaska Department of Revenue, Fred Alger Management Inc., Confluence Investment Management LLC, Boston Advisors LLC and Bank of Montreal Can. Company insiders that have bought Jazz Pharmaceuticals stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $176.49.

How big of a company is Jazz Pharmaceuticals?

Jazz Pharmaceuticals has a market capitalization of $10.61 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,210 workers across the globe.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]


MarketBeat Community Rating for Jazz Pharmaceuticals (NASDAQ JAZZ)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  793 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  1,077
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.